AstraZeneca announces IMFINZI improvement in secondary endpoint of OS

Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) IMFINZI in combination with standard-of-care FLOT chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival, OS, versus chemotherapy alone. Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers. In the final OS analysis, results showed the IMFINZI and FLOT perioperative regimen reduced the risk of death by 22% compared with chemotherapy alone. Median OS was not yet reached for either arm. An estimated 69% of patients treated with the IMFINZI-based regimen were alive at three years compared with 62% in the FLOT-only arm.